Breaking News, Trials & Filings

Jubilant Therapeutics Receives FDA Clearance for JBI-802 IND

Phase 1/2a trial designed to define the safety profile and preliminary activity of JBI-802 in participants with advanced solid tumors.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Jubilant Therapeutics Inc, a biopharmaceutical company advancing small molecule precision therapeutics in oncology and autoimmune diseases, received clearance from the U.S. FDA for the investigational new drug application (IND) for JBI-802, a novel, oral, potent and selective dual inhibitor of LSD1 and HDAC6, for the treatment of small cell lung cancer (SCLC), treatment-induced neuro-endocrine prostate cancer (NEPC) and other mutation-defined neuroendocrine tumors.   The Phase 1/2a trial is an...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters